argenx registers Phase 3 trial of adimanebart in rare congenital myasthenic syndromes

argenx had one registry update this week, a newly posted Phase 3 trial for its investigational drug adimanebart.

• argenx registered NCT07746089, a Phase 3, randomized, placebo-controlled study called "CoMetS" testing intravenous adimanebart in participants at least 12 years old with DOK7-, MUSK-, AGRN-, or LRP4- Congenital Myasthenic Syndromes¹. The trial is not yet recruiting, with an estimated start of 2026-09 and primary completion in 2030-10¹, and plans to enroll 105 participants¹, with the primary endpoint being change from baseline at week 24 in 6MWT distance¹.